Retraction: Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression(PLoS ONE (2014) 9:6 (e98560) DOI: 10.1371/journal.pone.0098560);Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Liu, Zhen ^a   Duan, Zhi Jun ^a   Chang, Jiu Yang ^a   Zhang, Zhi Feng ^a   Chu, Rui ^a   Li, Yu Ng ^a   Dai, Ke Hang ^a   Mo, Guang Quan ^a   Chang, Qing Yong ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN E2; SINOMENINE; ANTINEOPLASTIC ANTIBIOTIC; CELECOXIB; MORPHINAN DERIVATIVE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CACO 2 CELL LINE; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; COX 2 GENE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; GENE ACTIVATION; GENE OVEREXPRESSION; INHIBITION KINETICS; MDR 1 GENE; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL SURVIVAL; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MORPHINANS; NF-KAPPA B; P-GLYCOPROTEIN; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84902438525     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0215388     Document Type: Erratum

References (40)

1. Saika K, Sobue T (2013) [Cancer statistics in the world]. Gan To Kagaku Ryoho 40: 2475-2480.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398. (Pubitemid 29222564)
3. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58. (Pubitemid 37328807)
4. Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206: 173-185. (Pubitemid 43199136)
5. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998-1009. (Pubitemid 43185280)
6. Chan K, Liu ZQ, Jiang ZH, Zhou H, Wong YF, et al. (2006) The effects of sinomenine on intestinal absorption of paeoniflorin by the everted rat gut sac model. J Ethnopharmacol 103: 425-432. (Pubitemid 43143379)
7. Liu ZQ, Jiang ZH, Liu L, Hu M (2006) Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. Pharm Res 23: 2768-2780. (Pubitemid 44885365)
8. Zhao Y, Li J, Yu K, Liu Y, Chen X (2007) Sinomenine inhibits maturation of monocyte-derived dendritic cells through blocking activation of NF-kappa B. Int Immunopharmacol 7: 637-645.
9. de Groot DJ, de Vries EG, Groen HJ, de Jong S (2007) Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 61: 52-69.
10. Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436. (Pubitemid 38050040)
11. Raspollini MR, Amunni G, Villanucci A, Boddi V, Taddei GL (2005) Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer 15: 255-260. (Pubitemid 40396961)
12. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, et al. (2005) Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90: 5754-5760. (Pubitemid 41415487)
13. Zrieki A, Farinotti R, Buyse M (2010) Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. Eur J Pharmacol 636: 189-197.
14. Chen C, Shen HL, Yang J, Chen QY, Xu WL (2011) Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 137: 9-17.
15. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, et al. (2007) Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43: 433-442.
16. Liu D, Liu Y, Liu M, Ran L, Li Y (2013) Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide. Future Oncol 9: 595-604.
17. Wang L, Meng Q, Wang C, Liu Q, Peng J, et al. (2013) Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-kappaB signaling inhibition. J Nat Prod 76: 909-914.
18. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, et al. (2010) Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol 65: 903-911.
19. Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, et al. (2008) Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res 32: 855-864.
20. Luo L, Sun YJ, Yang L, Huang S, Wu YJ (2013) Avermectin induces Pglycoprotein expression in S2 cells via the calcium/calmodulin/NF-kappaB pathway. Chem Biol Interact 203: 430-439.
21. Sun J, Yeung CA, Co NN, Tsang TY, Yau E, et al. (2012) Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-kappaB in R-HepG2 cell line. PLoS One 7: e40720.
22. Dorai T, Aggarwal BB (2004) Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-140. (Pubitemid 39370030)
23. Shain KH, Dalton WS (2001) Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 1: 69-78.
24. Andorfer P, Rotheneder H (2013) Regulation of the MDR1 promoter by E2F1 and EAPP. FEBS Lett 587: 1504-1509.
25. Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M (2013) MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int 2013: 241763.
26. Xing AY, Shi DB, Liu W, Chen X, Sun YL, et al. (2013) Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. Exp Mol Pathol 94: 481-485.
27. He X, Wang J, Guo Z, Liu Q, Chen T, et al. (2005) Requirement for ERK activation in sinomenine-induced apoptosis of macrophages. Immunol Lett 98: 91-96. (Pubitemid 40409823)
28. Wang Y, Fang Y, Huang W, Zhou X, Wang M, et al. (2005) Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J Ethnopharmacol 98: 37-43. (Pubitemid 40349165)
29. Tsai TH, Wu JW (2003) Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats. Life Sci 72: 2413-2426.
30. Hong Y, Yang J, Shen X, Zhu H, Sun X, et al. (2013) Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells. Cancer Immunol Immunother 62: 447-454.
31. Oh YC, Kang OH, Kim SB, Mun SH, Park CB, et al. (2012) Anti-inflammatory effect of sinomenine by inhibition of pro-inflammatory mediators in PMA plus A23187-stimulated HMC-1 Cells. Eur Rev Med Pharmacol Sci 16: 1184-1191.
32. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005) Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23: 254-266. (Pubitemid 46206877)
33. Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, et al. (2007) P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 67: 4915-4923. (Pubitemid 46910199)
34. Lee JY, Tanabe S, Shimohira H, Kobayashi Y, Oomachi T, et al. (2007) Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistanceassociated protein in canine transitional cell carcinoma. Res Vet Sci 83: 210-216. (Pubitemid 46971710)
35. Miller B, Patel VA, Sorokin A (2006) Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein). J Am Soc Nephrol 17: 977-985.
36. Baeuerle PA (1998) Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 8: R19-22.
37. Thanos D, Maniatis T (1995) NF-kappa B: a lesson in family values. Cell 80: 529-532.
38. Neuschafer-Rube F, Pathe-Neuschafer-Rube A, Hippenstiel S, Kracht M, Puschel GP (2013) NF-kappaB-dependent IL-8 induction by prostaglandin E(2) receptors EP(1) and EP(4). Br J Pharmacol 168: 704-717.
39. Choi YH, Back KO, Kim HJ, Lee SY, Kook KH (2013) Pirfenidone attenuates IL-1beta-induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF-kappaB activity. Exp Eye Res 113: 1-8.
40. Xu X, Chen X, Li Y, Cao H, Shi C, et al. (2013) Cyclooxygenase-2 regulated by the nuclear factor-kappaB pathway plays an important role in endometrial breakdown in a female mouse menstrual-like model. Endocrinology 154: 2900-2911.